ERBB2 and breast carcinoma: This study highlights the significant role of TRIM24 and H3K23ac in breast cancer, suggesting that TRIM24 small-molecule inhibitors could benefit estrogen receptor- and progesterone receptor-negative or HER2-positive patients [17].